MCap chemotherapy for pseudomyxoma peritonei
Author Information
Author(s): Farquharson A L, Pranesh N, Witham G, Swindell R, Taylor M B, Renehan A G, Rout S, Wilson M S, O'Dwyer S T, Saunders M P
Primary Institution: Christie Hospital NHS Foundation Trust, Manchester, UK
Hypothesis
A combination of concurrent mitomycin C and capecitabine (MCap) would benefit patients with advanced pseudomyxoma peritonei.
Conclusion
The study shows that over one-third of patients with advanced unresectable pseudomyxoma peritonei benefit from MCap chemotherapy without high rates of severe toxicity.
Supporting Evidence
- 15 out of 39 assessable patients (38%) benefited from chemotherapy.
- Grade 3/4 toxicity rates were low at 6%.
- 69% of patients felt their Global Health Status improved during chemotherapy.
Takeaway
Doctors tested a new medicine on sick patients to see if it helped them feel better, and it worked for some of them.
Methodology
Patients received mitomycin C and capecitabine in a 3-weekly cycle, with response assessed by CT scans and serum tumour markers.
Limitations
The study was non-randomised and did not quantify disease response using volume-based criteria.
Participant Demographics
Median age was 59 years, with 28 females and 12 males; most had undergone previous surgeries.
Statistical Information
P-Value
0.001 for CEA, 0.002 for CA125
Confidence Interval
95% CIs: 25, 54% for response rate
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website